iShares Biotechnology ETF $IBB Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. reduced its position in iShares Biotechnology ETF (NASDAQ:IBB) by 52.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,204,046 shares of the financial services provider’s stock after selling 1,343,824 shares during the period. Goldman Sachs Group Inc. owned approximately 2.44% of iShares Biotechnology ETF worth $203,207,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of IBB. BNP Paribas Financial Markets lifted its stake in shares of iShares Biotechnology ETF by 313.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,915,395 shares of the financial services provider’s stock valued at $276,526,000 after purchasing an additional 1,451,820 shares in the last quarter. WestEnd Advisors LLC acquired a new position in shares of iShares Biotechnology ETF in the 4th quarter valued at about $106,276,000. Truist Financial Corp lifted its stake in shares of iShares Biotechnology ETF by 2,239.6% in the 4th quarter. Truist Financial Corp now owns 642,023 shares of the financial services provider’s stock valued at $108,354,000 after purchasing an additional 614,582 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in shares of iShares Biotechnology ETF in the 3rd quarter valued at about $65,083,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of iShares Biotechnology ETF by 27.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,060,048 shares of the financial services provider’s stock valued at $153,039,000 after purchasing an additional 226,852 shares in the last quarter. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Down 1.7%

NASDAQ IBB opened at $168.44 on Friday. iShares Biotechnology ETF has a 1-year low of $123.61 and a 1-year high of $179.64. The business’s 50-day simple moving average is $169.95 and its 200-day simple moving average is $170.55.

iShares Biotechnology ETF Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 20th. Stockholders of record on Tuesday, March 17th were paid a $0.1218 dividend. This represents a $0.49 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend was Tuesday, March 17th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.